---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Access and coverage questions"
description: "Access and coverage questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Patient support, Cost and coverage, Prior authorization, and Access support. Questions: Is there a Kisqali ECG monitoring program? How much do patients pay out of pocket for Kisqali? Is there a Kisqali copay card (Co-Pay Plus)? Can Medicare patients use the Kisqali copay card? 9 further questions follow. 13 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Access and coverage questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications](https://www.evicenter.com/medical-information/kisqali).

## Patient support

<a id="kisqali-ecg-program"></a>

### Is there a Kisqali ECG monitoring program?

> “The KISQALI ECG Device Monitoring Program can provide you or your patients with a KardiaMobile 6L ECG device”

Source: [KISQALI: Scheduled Assessments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/scheduled-assessments#:~:text=The%20KISQALI%20ECG%20Device%20Monitoring,a%20KardiaMobile%206L%20ECG%20device)

> “Direct-to-Patient option designed so patients can complete their ECG without a trip to the office”

Source: [KISQALI: Scheduled Assessments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/scheduled-assessments#:~:text=Direct%2Dto%2DPatient%20option%20designed%20so%20patients,a%20trip%20to%20the%20office)

> “There is no direct cost to you or your patients for participating in this program”

Source: [KISQALI: Scheduled Assessments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/scheduled-assessments#:~:text=There%20is%20no%20direct%20cost,for%20participating%20in%20this%20program)

> “Limitations apply. KISQALI ECG Device Monitoring Program is only permitted to be used for monitoring or evaluating a patient for the current or potential administration of ribociclib. The equipment or services are not permitted to be used for any purpose outside of the scope of the program. You must not bill any entity or person for any equipment or services relating to the provision or interpretation of the ECG. In the event that you fail to abide by the rules of the KISQALI ECG Device Monitoring Program, your participation in the program may be terminated or modified at any time without prior notice, and you may be subject to additional remedies. Additional terms and conditions apply. 
>
> Sunshine Act costs may apply.”

Source: [KISQALI: Scheduled Assessments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/scheduled-assessments#:~:text=Limitations%20apply.%20KISQALI%20ECG%20Device,Sunshine%20Act%20costs%20may%20apply.)

<a id="kisqali-patient-support"></a>

### What does Novartis Patient Support offer for Kisqali patients?

> “Novartis Patient Support™ offers a dedicated team to help provide a range of support services for your patients—from insurance and financial to clinical testing and ongoing support.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Novartis%20Patient%20Support%E2%84%A2%20offers%20a,clinical%20testing%20and%20ongoing%20support.)

> “Help navigating the insurance process, including benefits verification and support with the prior authorization (PA) and appeals processes.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Help%20navigating%20the%20insurance%20process%2C,authorization%20%28PA%29%20and%20appeals%20processes.)

> “To learn more, contact your dedicated Novartis Patient Support Team at 866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=To%20learn%20more%2C%20contact%20your,8%3A00%20PM%20ET%2C%20excluding%20holidays.)

## Cost and coverage

<a id="kisqali-out-of-pocket-cost"></a>

### How much do patients pay out of pocket for Kisqali?

> “For Medicare members, nearly 90% of KISQALI out-of-pocket costs were between $0 and $20 per month<sup>1</sup>”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=For%20Medicare%20members%2C%20nearly%2090%25,between%20%240%20and%20%2420%20per)

> “For patients with commercial insurance, approximately 80% of KISQALI out-of-pocket costs were between $0 and $50 per month<sup>1</sup>”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=For%20patients%20with%20commercial%20insurance%2C,between%20%240%20and%20%2450%20per)

> “1. Data on file. Kisqali IQVIA data through November 2025. Novartis Pharmaceuticals Corp; 2026.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=1.%20Data%20on%20file.%20Kisqali,2025.%20Novartis%20Pharmaceuticals%20Corp%3B%202026.)

Note: The figures are the manufacturer's statements based on IQVIA data through November 2025, as shown on the page captured November 13, 2026. No list price is stated on the captured pages.

<a id="kisqali-copay-card"></a>

### Is there a Kisqali copay card (Co-Pay Plus)?

> “Patients may be eligible for immediate co-pay savings on their next prescription of KISQALI tablets and/or FEMARA® (including generic letrozole).
>
> Eligible patients with private insurance may pay as little as $0 for KISQALI.*
>
> Have an annual benefit limit per calendar year.*”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Patients%20may%20be%20eligible%20for,benefit%20limit%20per%20calendar%20year.%2A)

> “Offer valid only when used with commercial health insurance. Offer is not available where:
>
> the patient has federal or state health plan benefits (e.g., Medicare, Medicaid, TRICARE, VA);
> the health plan reimburses for the entire cost of the drug;
> the health plan provides no coverage for the drug; or
> prohibited by law.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Offer%20valid%20only%20when%20used,prohibited%20by%20law.)

> “The amount of funding available from the Program is subject to an annual limit.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=The%20amount%20of%20funding%20available,subject%20to%20an%20annual%20limit.)

> “The patient is responsible for all costs once available funding from the Program is exhausted.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=The%20patient%20is%20responsible%20for,from%20the%20Program%20is%20exhausted.)

Note: The captured pages do not state the dollar amount of the annual benefit limit.

<a id="kisqali-copay-medicare"></a>

### Can Medicare patients use the Kisqali copay card?

> “Offer valid only when used with commercial health insurance. Offer is not available where:
>
> the patient has federal or state health plan benefits (e.g., Medicare, Medicaid, TRICARE, VA);”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Offer%20valid%20only%20when%20used,%28e.g.%2C%20Medicare%2C%20Medicaid%2C%20TRICARE%2C%20VA%29%3B)

<a id="kisqali-coverage"></a>

### Is Kisqali covered by insurance and Medicare?

> “More than 9 out of 10 patients have preferred formulary coverage for KISQALI<sup>2,*</sup>”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=More%20than%209%20out%20of%2010%20patients%20have%20preferred%20formulary%20coverage%20for)

> “*>98% unrestricted coverage in Commercial and Medicare, based on MMIT data, as of June 2026.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=%2A%3E98%25%20unrestricted%20coverage%20in%20Commercial,data%2C%20as%20of%20June%202026.)

> “Novartis does not guarantee payment or coverage for any product or service. Actual coverage and reimbursement decisions are made by individual payers following receipt of claims. Coverage is subject to change by the relevant payer.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Novartis%20does%20not%20guarantee%20payment,change%20by%20the%20relevant%20payer.)

> “PA is the main coverage request for KISQALI.”

Source: [KISQALI: Support Guide, page 18, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=18)

Note: The coverage figures are the manufacturer's statements based on MMIT data as of June 2026, as shown on the page captured November 13, 2026. The page does not define unrestricted coverage; the last passage is from the KISQALI Access Support Guide that the page links.

<a id="kisqali-coverage-lookup"></a>

### How can I check Kisqali coverage for a specific health plan?

> “Use the Local Insurance Lookup Tool to view local plan-level Kisqali coverage by ZIP code or NPI.”

Source: [KISQALI: Local Insurance Coverage | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/local-insurance-coverage#:~:text=Use%20the%20Local%20Insurance%20Lookup,by%20ZIP%20code%20or%20NPI.)

## Prior authorization

<a id="kisqali-prior-authorization"></a>

### Does Kisqali need prior authorization?

> “PA is the main coverage request for KISQALI.”

Source: [KISQALI: Support Guide, page 18, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=18)

> “More than 90% of KISQALI PAs are approved in less than 24 hours<sup>3</sup>”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=More%20than%2090%25%20of%20KISQALI%20PAs%20are%20approved%20in%20less%20than%2024)

> “3. Data on file. Kisqali CMM AMP data review February 2026. Novartis Pharmaceuticals Corp; 2026.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=3.%20Data%20on%20file.%20Kisqali,2026.%20Novartis%20Pharmaceuticals%20Corp%3B%202026.)

Note: The first passage is from the KISQALI Access Support Guide that the Novartis Patient Support page links. The approval figure is the manufacturer's statement based on its February 2026 data review.

<a id="kisqali-appeal"></a>

### How can a Kisqali coverage denial be appealed?

> “If a patient is denied coverage and the HCP wishes to appeal the health plan’s decision, it is typically required that the HCP explain 
> their clinical rationale for prescribing KISQALI in a Letter of Appeal. This letter addresses each specific reason given for the denial. 
> Review the reason for the denial from the denial letter. Provide clinically relevant and patient-specific information as a guide to 
> address the denial reason in your Letter of Appeal as well as your clinical rationale for prescribing KISQALI.”

Source: [KISQALI: Support Guide, page 11, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=11)

> “We have included sample Letters of Appeal and Medical Necessity. The Letter of Medical Necessity may be used to support a 
> PA request or appeal. A plan may require a Letter of Medical Necessity in certain situations, such as when requesting a formulary 
> exception. Each letter should be submitted with a copy of the patient’s relevant medical records.”

Source: [KISQALI: Support Guide, page 11, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=11)

Note: The passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links.

## Access support

<a id="kisqali-bridge-program"></a>

### Can privately insured patients get free Kisqali after a coverage denial (Bridge Program)?

> “Up to 5 free treatment cycles of KISQALI for eligible patients through the Bridge Program<sup>†</sup> while health plan coverage is pursued.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Up%20to%205%20free%20treatment,health%20plan%20coverage%20is%20pursued.)

> “<sup>†</sup>The Bridge Program applies to KISQALI and the KISQALI FEMARA Co-Pack only. Eligible patients must have private insurance, a valid prescription for KISQALI or the KISQALI FEMARA Co-Pack, and a denial of insurance coverage based on a prior authorization requirement. Program requires the submission of a prior authorization and/or appeal of the coverage denial within the first 90 days of enrollment to remain eligible. Program provides KISQALI for free to eligible patients for up to 5 months, or until they receive insurance coverage approval, whichever occurs earlier.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Bridge%20Program%20applies%20to%20KISQALI,coverage%20approval%2C%20whichever%20occurs%20earlier.)

> “Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Program%20is%20not%20available%20to,other%20federal%20or%20state%20program.)

<a id="kisqali-patient-assistance"></a>

### Is there a Kisqali patient assistance program for uninsured patients?

> “Novartis Patient Assistance Foundation, Inc. (NPAF), an independent 501(c)(3) non-profit organization, provides Novartis medications free of cost to eligible patients who have limited or no prescription insurance coverage and cannot afford the cost of their medication.
>
> To be eligible, patients must:
>
> Reside in the United States or a US territory
>
> Be treated by a licensed US health care provider on an outpatient basis
>
> Meet income and insurance guidelines
>
> Visit PAP.Novartis.com or call NPAF at 800-277-2254 to learn more about eligibility and how to apply.”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Novartis%20Patient%20Assistance%20Foundation%2C%20Inc.,eligibility%20and%20how%20to%20apply.)

<a id="kisqali-start-form"></a>

### How do you enroll a patient in Kisqali patient support (Start Form)?

> “Getting Patients Started With Novartis Patient Support
>
> Download the Start Form
>
> Complete Start Form, capture consent, and submit
>
> Fill out all required sections with the patient. Ensure both you and the patient sign to capture consent
> Fax completed form to Novartis Patient Support at 800-414-3518
> Missing information may result in delays. Novartis Patient Support will contact you to request any incomplete information”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Getting%20Patients%20Started%20With%20Novartis,to%20request%20any%20incomplete%20information)

> “Fill out the electronic Start Form on the CoverMyMeds® portal by visiting www.CoverMyMeds.health”

Source: [KISQALI: Novartis Patient Support | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/novartis-patient-support#:~:text=Download-,Fill%20out%20the%20electronic%20Start%20Form%20on%20the%20CoverMyMeds%C2%AE%20portal,by%20visiting%20www.CoverMyMeds.health)

<a id="kisqali-specialty-pharmacy"></a>

### Which specialty pharmacies dispense Kisqali?

> “KISQALI prescriptions can be filled at an in-network Specialty Pharmacy, 
> a hospital outpatient pharmacy, or an outpatient clinic/practice pharmacy”

Source: [KISQALI: Support Guide, page 10, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=10)

> “Specialty Pharmacy Network for KISQALI
> In addition to hospital outpatient pharmacies or outpatient clinic/practice pharmacies, the intended network will include the full-service specialty pharmacies 
> listed below.*
> Novartis may modify this network at any time without notice.
> PHARMACY
> PHONE
> FAX
> HOURS OF OPERATION
> AcariaHealth Specialty Pharmacy
> 1-800-511-5144
> 1-877-541-1503
> 24/7
> Accredo Specialty Pharmacy
> 1-877-732-3431
> 1-888-302-1028
> 24/7
> Walgreens Specialty Pharmacy
> 1-800-516-9180
> N/A
> 8 am to 8 pm ET, Mon to Fri;
> 8 am to 5 pm ET, Sat
> BioPlus Specialty Pharmacy
> 1-866-514-8082
> 1-800-269-5493
> 24/7
> Biologics by McKesson
> 1-800-850-4306
> 1-800-823-4506
> 24/7
> CVS Specialty Pharmacy
> 1-800-237-2767
> 1-800-323-2445
> 8 am to 8 pm ET, Mon to Fri
> CenterWell Specialty Pharmacy
> 1-800-486-2668
> 1-877-405-7940
> 8 am to 11 pm ET, Mon to Fri;
> 8 am to 6:30 pm ET, Sat
> Onco360 Oncology Pharmacy
> 1-877-662-6633
> 1-877-662-6355
> 24/7
> Optum Specialty Pharmacy
> 1-877-445-6874
> 1-877-342-4596
> 24/7”

Source: [KISQALI: Support Guide, page 21, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=21)

> “Novartis does not recommend or require the use of any particular pharmacy. Please refer to the patient’s health plan for requirements regarding use of particular specialty pharmacies.”

Source: [KISQALI: Support Guide, page 21, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11586153_Kisqali_Pan_Indication_Access_Support_Guide_PDF_5-26/FA-11586153.PDF#page=21)

Note: The passages are from the KISQALI Access Support Guide (May 2026) that the Novartis Patient Support page links; the table lists each pharmacy followed by its phone number, fax number, and hours. The Specialty Pharmacy Network flashcard of October 2025 on the resources page lists the same pharmacies with different phone and fax numbers for Walgreens Specialty Pharmacy and CVS Specialty Pharmacy and different hours for BioPlus Specialty Pharmacy and Biologics by McKesson.

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
